{"url_path":"/sec/ganx/8-k/2026-06-25/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-077820-index.html","accession_number":"0001104659-26-077820","cik":"0001819411","ticker":"GANX","issuer_name":"Gain Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-077820-index.html","primary_entity_key":"0001819411","primary_entity_name":"Gain Therapeutics, Inc."},"word_count":291,"has_tables":true,"body_markdown":"false\n0001819411\n\n0001819411\n\n2026-06-24\n2026-06-24\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT REPORT**\n\n** **\n\n**PURSUANT TO SECTION 13 OR 15(d) OF THE**\n\n**SECURITIES\nEXCHANGE ACT OF 1934**\n\n \n\nDate of Report (Date of earliest event reported):**June 24, 2026**\n\n \n \n \n\n**Gain Therapeutics, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n** **\n\n**Delaware**\n \n**001-40237**\n \n**85-1726310**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission File\nNumber)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**4800 Montgomery Lane****, Suite 220**\n\n******Bethesda****, Maryland** **20814**\n\n(Address of principal\nexecutive offices) (Zip Code)\n\n ****\n\n**(301****)\n500-1556**\n\n(Registrant’s telephone number, including area code)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n** **\n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\nfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨\n\n** **\n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n** **\n\n****\n\n**Title\nof each class:**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which Registered**\n\nCommon Stock, par value $0.0001\n \nGANX\n \nThe\nNasdaq Stock\nMarket LLC"}